Eugene Seymour - NanoViricides CEO, Director
| NNVC Stock | USD 1.12 0.02 1.82% |
CEO
Dr. Eugene Seymour, M.D., MPH, is Chief Executive Officer, Director of NanoViricides, Inc. From 1996 until May 2005 he was Chief Executive Officer and a director of the Company since consummation of the merger on June 1, 2005. From 1996 until May 2005 he was a private investor and has held no corporate positions. During this period he formed a nonprofit foundation that funded both testing and training programs for health workers in Asia and Africa. He was a consultant to the UN Global Program on AIDS and was sent to several countries, to interact with local physicians and assist them in setting up testing programs. Dr. Seymour obtained a Masters degree in the Epidemiology of Infectious Diseases at UCLA in addition to his medical degree. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. He left UCLA after two years and joined the USC faculty as Associate Professor since 2013.
| Age | 74 |
| Tenure | 11 years |
| Address | 1 Controls Drive, Shelton, CT, United States, 06484 |
| Phone | 203 937 6137 |
| Web | https://www.nanoviricides.com |
NanoViricides Management Efficiency
The company has return on total asset (ROA) of (0.3595) % which means that it has lost $0.3595 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.579) %, meaning that it created substantial loss on money invested by shareholders. NanoViricides' management efficiency ratios could be used to measure how well NanoViricides manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to -0.49. In addition to that, Return On Capital Employed is expected to decline to -0.52. At present, NanoViricides' Total Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 22 M, whereas Non Current Assets Total are forecasted to decline to about 6.7 M.Similar Executives
| Found 6 records | CEO Age | ||
| William Stilley | Adial Pharmaceuticals | 49 | |
| Cary MBA | Adial Pharmaceuticals | 63 | |
| Michael Bristow | ARCA Biopharma | 70 | |
| Paul Wagner | Forte Biosciences | 54 | |
| Tiago MD | Pasithea Therapeutics Corp | 46 | |
| LLM JD | Tempest Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.36 |
NanoViricides Leadership Team
Elected by the shareholders, the NanoViricides' board of directors comprises two types of representatives: NanoViricides inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NanoViricides. The board's role is to monitor NanoViricides' management team and ensure that shareholders' interests are well served. NanoViricides' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NanoViricides' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stanley Glick, Independent Director | ||
| Irach Taraporewala, CEO | ||
| Randall Barton, Chief Officer | ||
| Milton Boniuk, Independent Director | ||
| Eugene Seymour, CEO, Director | ||
| Meeta Vyas, Interim CFO | ||
| Anil Diwan, Chairman and President and Secretary | ||
| Mark Day, Independent Director | ||
| Mukund Kulkarni, Independent Director | ||
| BS MBA, Chief Officer | ||
| James Sapirstein, Independent Director |
NanoViricides Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NanoViricides a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 7.71 M | ||||
| Shares Outstanding | 11.78 M | ||||
| Shares Owned By Insiders | 4.61 % | ||||
| Shares Owned By Institutions | 10.29 % | ||||
| Number Of Shares Shorted | 98.92 K | ||||
| Price To Earning | (6.02) X | ||||
| Price To Book | 1.18 X | ||||
| EBITDA | (7.84 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NanoViricides. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for NanoViricides Stock analysis
When running NanoViricides' price analysis, check to measure NanoViricides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoViricides is operating at the current time. Most of NanoViricides' value examination focuses on studying past and present price action to predict the probability of NanoViricides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoViricides' price. Additionally, you may evaluate how the addition of NanoViricides to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is NanoViricides' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Return On Assets (0.36) | Return On Equity (0.58) |
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.